Traceless aptamer-mediated isolation of CD8<sup>+</sup> T cells for chimeric antigen receptor T-cell therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31209354.
- Also identified by DOI 10.1038/s41551-019-0411-6 and PMC identifier 6783348.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor T-cell therapies using defined product compositions require high-purity T-cell isolation systems that, unlike immunomagnetic positive enrichment, are inexpensive and leave no trace on the final cell product. Here, we show that DNA aptamers (generated with a modified cell-SELEX procedure to display low-nanomolar affinity for the T-cell marker CD8) enable the traceless isolation of pure CD8<sup>+</sup> T cells at low cost and high yield. Captured CD8<sup>+</sup> T cells are released label-free by complementary oligonucleotides that undergo toehold-mediated strand displacement with the aptamer. We also show that chimeric antigen receptor T cells manufactured from these cells are comparable to antibody-isolated chimeric antigen receptor T cells in proliferation, phenotype, effector function and antitumour activity in a mouse model of B-cell lymphoma. By employing multiple aptamers and the corresponding complementary oligonucleotides, aptamer-mediated cell selection could enable the fully synthetic, sequential and traceless isolation of desired lymphocyte subsets from a single system.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- SELEX Aptamer Technique